What Tysabri Patients Should Know About PML Risk Over Time

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specialized Risk Awareness

If you or a loved one has been on Tysabri for multiple years, you may have questions about the risk of progressive multifocal leukoencephalopathy (PML). The medical community has long emphasized that understanding a patient's treatment timeline is essential for managing this rare but serious brain infection. This page reviews the evidence on exposure duration, risk factors, and recommended monitoring.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease when other treatments are not tolerated. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes evidence from FDA-approved labeling and clinical trial data to describe the medical risks, clinical presentation, and legal considerations for affected patients. PML is an opportunistic viral infection of the brain caused by the JC virus, which typically only occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition presents with progressive neurological deficits, including cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Early recognition is critical because prompt withdrawal of Tysabri may improve outcomes, though many patients still experience permanent disability.

Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in MS but also impairs immune surveillance in the central nervous system, allowing JC virus reactivation. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 MS patients treated for a median of 120 weeks, both of whom had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML. These data underscore that PML risk is present even with monotherapy, though concomitant immunosuppressants may further elevate risk.

Mechanistic Pathways Linking Tysabri to PML

The primary mechanism is immune surveillance failure. By blocking lymphocyte trafficking into the brain, Tysabri reduces the ability of the immune system to control JC virus replication in oligodendrocytes. The virus then destroys these cells, causing demyelination and progressive neurological injury. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.

Adequacy of Warnings and Legal Considerations

The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning explicitly lists risk factors and instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed prescribing and monitoring. Despite these warnings, some patients and clinicians may not fully appreciate the magnitude of risk, particularly in the absence of prior immunosuppressant use or with shorter treatment durations. Patients who develop PML after Tysabri therapy may have legal claims if they believe the warnings were inadequate or if they were not properly informed of the risks. Key considerations include whether the prescribing physician discussed the risk of PML, whether the patient was tested for anti-JCV antibodies before and during treatment, and whether alternative therapies were considered. The timeline between exposure and documented harm is critical: PML typically occurs after prolonged treatment, but cases have been reported after as few as eight doses. Legal evaluation often requires expert medical review to establish causation and to determine whether the manufacturer's warnings were sufficient to allow informed decision-making.

Timeline Between Exposure and Documented Harm

In clinical trials, PML developed after a median of 120 weeks of Tysabri treatment in MS patients, and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability means that patients may be at risk even with shorter exposure, especially if they have other risk factors such as anti-JCV antibodies or prior immunosuppressant use. The latency period complicates legal claims because symptoms may not appear until months or years after treatment initiation, and the patient's medical history must be carefully documented.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The risk is documented in FDA-approved labeling and clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML in Tysabri patients?

Symptoms include progressive neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis involves brain MRI and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical for improving outcomes.

What legal options are available for patients who developed PML from Tysabri?

Patients may have legal claims if they believe warnings were inadequate or they were not properly informed of risks. Key factors include whether the physician discussed PML risk, anti-JCV antibody testing, and consideration of alternative therapies. Legal evaluation requires expert medical review to establish causation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.